ASXC - Asensus Surgical: Digging In Against Incumbents In The Robotic Surgery Field
- Asensus develops and markets an advanced digital laparoscopy system, Senhance.
- Formerly known as TransEnterix, Asensus's share price went on a major bull run in January/February, hitting a high of $6.5, but has since settled at $2.3.
- The company earned revenues of just $3.2m in FY20 and is having to lease its products to hospitals in the hope of making delayed sales.
- The company has a fearsome competitor in Intuitive Surgical and its Da Vinci system.
- A 5% market share of the laparoscopy market would support a share price target of >$7, in my view, and that could be achievable. Marketing, favourable reviews and news flow can keep the share price up as the company tries to ramp up sales.
For further details see:
Asensus Surgical: Digging In Against Incumbents In The Robotic Surgery Field